secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-06-30T20:06:32+00:00
Accession:  0001867096-26-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris appoints Nerissa Kreher to board; CEO John Shannon named Chair
--------------------------------------------------------------------

- Dr. Nerissa Kreher appointed to board effective July 1, 2026, expanding board to eight members.
- CEO John Shannon named Chair of the Board effective July 1, 2026.
- Marla Persky transitions to Lead Independent Director.
- Dr. Kreher is CMO of Alltrna and has over 20 years of rare disease experience.
- Dr. Kreher received initial equity award of ~$450,000 in options and RSUs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000048/0001867096-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000048/xers-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer